QCOR News 88.83 05/30/2014 05:24:19 Questcor Pharmaceuticals

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Questcor Pharmaceuticals (QCOR) 88.83 $QCOR

Shares of QCOR Up 31.2% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu May 29, 11:00AM CDT
SmarTrend identified an Uptrend for Questcor Pharmaceuticals (NASDAQ:QCOR) on April 1st, 2014 at $67.41. In approximately 2 months, Questcor Pharmaceuticals has returned 31.17% as of today's recent price of $88.42.

Kors, Qihoo Among 5 Top Stocks With 99 EPS Ratings
at Investor's Business Daily - Thu May 29, 7:02AM CDT
Michael Kors continued to show its dominance in the luxury-brand market, posting fourth-quarter earnings that topped analyst estimates Wednesday. The company is among highly rated firms that have strong long-term fundamentals. The Top Fundamentals...

Questcor Pharmaceuticals Set to Possibly Rebound After Yesterday's Selloff of 1.26%
Comtex SmarTrend(R) - Wed May 28, 5:39PM CDT
Questcor Pharmaceuticals (NASDAQ:QCOR) traded in a range yesterday that spanned from a low of $88.75 to a high of $90.48. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $89.75 on volume of 702,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.

Questcor Receives "Recognition of Appreciation" Award from MS Views & News
PR Newswire - Wed May 28, 2:28PM CDT
Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced that it has been honored with a "Recognition of Appreciation" Award from MS Views & News, Inc., a leading multiple sclerosis (MS) education, information and advocacy organization.

Free Speech and the FDA: Are Radical Changes Incoming?
George Budwell, The Motley Fool - Motley Fool - Mon May 26, 9:05AM CDT
A storm is brewing over the promotion of drugs for off-label uses that could fundamentally alter the pharmaceutical industry. It all started nearly 18 months ago when a conviction of a pharmaceutical sales rep named Alfred Caronia, for promoting the...

3 Stocks Near 52-Week Highs Worth Selling
Sean Williams, The Motley Fool - Motley Fool - Thu May 22, 6:45PM CDT
The broader market may suffer through its tumultuous one- or two-day pullbacks now and then, but the fact that three-out-of-eight stocks are within 10% or less of a fresh 52-week high demonstrates how resilient this market has been. For skeptics like...

Uptrend Call Working As Questcor Pharmaceuticals Stock Rises 38.4% (QCOR)
Comtex SmarTrend(R) - Thu May 22, 9:36AM CDT
SmarTrend identified an Uptrend for Questcor Pharmaceuticals (NASDAQ:QCOR) on April 1st, 2014 at $67.41. In approximately 2 months, Questcor Pharmaceuticals has returned 38.41% as of today's recent price of $93.30.

Senior Level Appointments, Collaboration Agreements, Prestigious Awards Nominations, and Company Updates - Analyst Notes on Biogen Idec, Questcor, Zimmer, Cigna and Ctrip.com
PR Newswire - Thu May 22, 7:40AM CDT
Today, Analysts Review released its analysts' notes regarding Biogen Idec Inc. (NASDAQ: BIIB), Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), Zimmer Holdings, Inc. (NYSE: ZMH), Cigna Corporation (NYSE: CI) and Ctrip.com International Ltd. (NASDAQ: CTRP). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2808-100free.

Downgrade Alert for Questcor Pharmaceuticals (QCOR)
Comtex SmarTrend(R) - Tue May 20, 6:56AM CDT
Questcor Pharmaceuticals (NASDAQ:QCOR) was downgraded from Buy to Neutral at Mizuho today. The stock closed yesterday at $92.08 on volume of 2.0 million shares, below average daily volume of 3.5 million. Questcor Pharmaceuticals, Inc. develops and commercializes novel central nervous system-focused therapeutics that address significant unmet medical needs. The Company's primary product is a natural source adrenocorticotropic hormone indicated for the treatment of acute exacerbations of multiple sclerosis, as well as a number of other conditions.

Clinical Trial Results, Development Collaboration, Board Appointments, Presentations, and Quarterly Results - Analyst Notes on Gilead, Questcor, Vertex, ARIAD and Puma Biotechnology
PR Newswire - Tue May 20, 6:40AM CDT
Today, Analysts Review released its analysts' notes regarding Gilead Sciences, Inc. (NASDAQ: GILD), Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX), ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) and Puma Biotechnology, Inc. (NYSE: PBYI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2665-100free.

SmarTrend Watching for Potential Pullback in Shares of Questcor Pharmaceuticals After 1.80% Gain
Comtex SmarTrend(R) - Fri May 16, 4:18PM CDT
Questcor Pharmaceuticals (NASDAQ:QCOR) traded in a range yesterday that spanned from a low of $88.28 to a high of $90.93. Yesterday, the shares gained 1.8%, which took the trading range above the 3-day high of $88.94 on volume of 1.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Today's Stocks Driving Success For The Health Care Sector
at The Street - Fri May 16, 12:03PM CDT
TheStreet highlights 3 stocks pushing the health care sector higher today.

Questcor (QCOR) is Overbought: Is A Drop Coming? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu May 15, 8:00AM CDT
Questcor (QCOR) is Overbought: Is A Drop Coming?

Questcor Enters Into Development Collaboration Agreement Covering Novel Receptor-Selective Melanocortin Peptides
PR Newswire - Wed May 14, 8:00AM CDT
Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) today announced that it has entered into a development collaboration agreement with an undisclosed privately held European company to develop novel melanocortin peptides. The collaboration includes an option to acquire the technology during clinical development. Along with the June 2013 acquisition of Synacthen®, this transaction significantly expands Questcor's portfolio of melanocortin therapeutics and further establishes the company as the leader in this important emerging field of medicine.

Post Earnings Update: Questcor Pharmaceuticals Has Climbed 10.5% Higher in Past 2 Weeks (QCOR)
Comtex SmarTrend(R) - Mon May 12, 11:42AM CDT
When Questcor Pharmaceuticals (NASDAQ:QCOR) reported earnings 14 days ago on April 28th, 2014, analysts, on average, expected the company to report earnings of $1.61 on sales of $240.8 million. Questcor Pharmaceuticals actually reported earnings of $1.51 per share on sales of $227.1 million, missing EPS estimates by $0.10 and missing revenue estimates by $13.6 million. Since the company's report, shares of Questcor Pharmaceuticals have risen from $79.05 to $87.34, representing a gain of 10.5% in the past 14 days.

Mallinckrodt Pharmaceuticals and Questcor Pharmaceuticals Announce Early Termination of HSR Act Waiting Period
Business Wire - Mon May 12, 6:01AM CDT
Mallinckrodt plc (NYSE: MNK), and Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR" , in connection with Mallinckrodt's proposed acquisition of Questcor, was terminated by the United States Federal Trade Commission on May 9, 2014.

Webcast Schedules, Clinical Study Results, Stock Price Movements, and Grants - Analyst Notes on Illumina, Questcor, Quest Diagnostics, Raytheon and Lockheed Martin
PR Newswire - Mon May 12, 6:00AM CDT
Today, Analysts Review released its analysts' notes regarding Illumina Inc. (NASDAQ: ILMN), Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), Quest Diagnostics Inc. (NYSE: DGX), Raytheon Co. (NYSE: RTN) and Lockheed Martin Corporation (NYSE: LMT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2321-100free.

Scanning Equities that Reached New highs -- Research on Energy Transfer Equity, Questcor Pharma, Health Net, and Molson Coors Brewing
PR Newswire - Thu May 08, 12:30PM CDT
The markets on Wednesday, May 07, 2014 ended on a mixed note as the Dow Jones Industrial Average finished the day at 16,518.54, up 0.72%, and the NASDAQ Composite closed at 4,067.67, down 0.32%. The S&P 500 finished the session 0.56% higher at 1,878.21. The gains were broad based as eight out of ten sectors ended the session in positive. Investor-Edge looks at some of the equities that hit a new 52-week high during the last session. These include Energy Transfer Equity L.P. (NYSE: ETE), Questcor Pharmaceuticals Inc. (NASDAQ: QCOR), Health Net Inc. (NYSE: HNT) and Molson Coors Brewing Company (NASDAQ: TAP). Free technical research on ETE, QCOR, HNT and TAP can be downloaded upon signing up at:

Valeant Q1 Mixed, But Strong 2014 Guidance Affirmed
at Investor's Business Daily - Thu May 08, 10:19AM CDT
Canadian drugmaker Valeant Pharmaceuticals International (VRX) reported a mixed but mostly in-line Q1 Thursday, as management continued to press its case for a merger with Allergan (AGN). Valeant's stock rose fractionally on the stock market today....
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 58

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
California Initiative Puts Missed Diagnoses in Focus

Updated Category News Views 161

When Reassurance Turns Into a Risk A clean scan can become a dangerous lullaby when symptoms refuse to leave. That is the hard, unsettling territory behind Hodes Milman’s new Missed Diagnosis Project: California, launched November 20, 2026. The statewide effort focuses on breast cancer diagnostic failures: scans read as benign when more scrutiny was warranted, referrals...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 58

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Kinross Lawsuit Puts Round Mountain Claims Under Fire

Updated Category News Views 85

A mine can swallow a rosy forecast faster than any spreadsheet admits. That is the ugly center of the proposed securities class action involving Kinross Gold: not merely that production guidance came down, but the allegation that investors were sold too much confidence before the operational reality at Round Mountain Phase S surfaced. NYSE:KGC dropped from $27.62 on...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 162

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
Charter Investigation Puts ACP Exit Claims Under Lens

Updated Category News Views 126

Charter’s ACP hangover has grown from an operating headache into a governance question. Kahn Swick & Foti said on November 20, 2026, that it has begun investigating whether Charter Communications officers or directors breached fiduciary duties or otherwise broke state or federal law. That is not a finding of wrongdoing, and investors ought to keep that distinction...

Continue Reading
Fraud0-FouAnalytics Takes Aim at Legacy Ad Verification

Updated Category News Views 144

Digital ad measurement has spent years grading its own homework, and that little arrangement may finally be getting some daylight. fraud0 and FouAnalytics say their expanded partnership will give advertisers impression-level visibility into where ads actually rendered, whether apparent humans engaged with them, and where wasted Google Ads spend might be recoverable. The...

Continue Reading
Midterm Voters Put Cost Relief Ahead of Washington Wars

Updated Category News Views 100

Gas pumps and medical bills have a way of humiliating every grand political slogan ever printed. Seven Letter Insight's latest post-election survey says confirmed 2026 midterm voters want the 120th Congress to deal with costs first, particularly gas prices, health care, restoring health care tax credits and energy bills. That is not a glamorous mandate. It is, however,...

Continue Reading
ASA’s 2026 Grants Push Dermatology Into New Terrain

Updated Category News Views 104

Thirteen Small Bets With Serious Human Stakes Skin science rarely gets the splashy headlines, yet it touches a staggering number of people and carries some very stubborn unanswered questions. American Skin Association’s 2026 grant class puts 13 awards across skin cancer and dermatologic disease, with a noticeable willingness to follow newer clinical terrain rather than...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 114

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring the Future of Palantir: A Promising Investment Opportunity

Updated Category News Views 200

The Rise of Palantir Technologies Palantir Technologies (NYSE: PLTR) has emerged as a notable force in the stock market, especially in the field of artificial intelligence (AI). Known for its complex data analytics platforms, Palantir was founded after the September 11 attacks to offer essential software solutions to federal intelligence agencies, assisting them in...

Continue Reading
Castellum, Inc. Achieves Record Revenue and Debt Reduction

Updated Category News Views 176

Castellum, Inc. Reports Impressive Q2 Financial Results Castellum, Inc. (NYSE-American: CTM), a prominent player in cybersecurity, electronic warfare, and software services directed towards the federal government, recently unveiled its financial results for the second quarter of 2025. The results showcase a record revenue performance, enhanced operational efficiencies,...

Continue Reading
Revolutionary Ultra H2 Wheelset by Superteam Wheels Debuts

Updated Category News Views 441

Introducing the Ultra H2 Wheelset Superteam Wheels, a notable name in the cycling industry, has taken a major step forward with the launch of their Ultra H2 Special Edition Wheelset. This new product is set to redefine the standards of performance wheels, appealing to cycling enthusiasts who seek the perfect blend of speed, reliability, and design. Advanced Technology at...

Continue Reading
Family Care Center's IOP Secures Three-Year CARF Accreditation

Updated Category News Views 200

Family Care Center Achieves Notable CARF Accreditation Family Care Center, a prominent national provider in behavioral health care, has recently announced a significant milestone: its intensive outpatient program (IOP) has earned a coveted three-year accreditation from the Commission on Accreditation of Rehabilitation Facilities (CARF). This accomplishment not only...

Continue Reading
Entergy Boosts Quarterly Dividend to Support Shareholders

Updated Category News Views 169

Entergy Announces Dividend Increase for Shareholders Entergy's board of directors has recently made a significant decision to enhance shareholder value. They declared a quarterly dividend payment of $0.64 per share, marking a notable increase of $0.04 per share. This increment reflects the company's ongoing commitment to rewarding its investors. Dividend Payment Schedule...

Continue Reading